8-K Announcements
6Material company update
Jan 6, 2026·SEC
Material company update
Nov 14, 2025·SEC
Material company update
Nov 13, 2025·SEC
Mersana Therapeutics remains in a precarious financial position, characterized by a reliance on volatile, non-recurring milestone payments that have failed to offset persistent operational losses. The company's transition from a $186.3M cash position in 2023Q3...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest Mar 2, 2026 | -$2.75+10.0% vs -$3.05 | — vs $5M |
Q4 2025 Nov 14, 2025 | -$1.51-4.9% vs -$1.44 | $11M-29.0% vs $16M |
Q3 2025 Aug 13, 2025 | -$4.87-29.9% vs -$3.75 | $3M-50.6% vs $6M |
Q2 2025 May 15, 2025 | -$4.75+1.3% vs -$4.81 | $3M-54.5% vs $6M |
Benchmark MRSN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Mersana Therapeutics, Inc. (MRSN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $29.08 | $145.36M | -2.06 | 9.88% | -170.86% | -505.14% | — | |
| $26.39 | $3.32B | -8.02 | -4.26% | -386.32% | -87.98% | — | |
| $17.64 | $1.56B | -5.36 | 627.84% | -87.6% | -372.94% | — | |
| $8.40 | $349.8M | -2470.59 | 10.37% | 69.76% | — | — | |
| $56.00 | $8.57B | 20.22 | 87.32% | 55.22% | 72.3% | — | |
| $57.66 | $1.91B | -5.93 | -43.89% | -287.84% | -37.99% | — |
Mersana Therapeutics, Inc. (MRSN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Mersana Therapeutics, Inc. (MRSN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jan 6, 2026·SEC
Nov 14, 2025·SEC
Nov 13, 2025·SEC
Get notified when MRSN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Mersana Therapeutics, Inc. (MRSN) stock FAQ — growth, dividends, profitability & financials explained
Mersana Therapeutics, Inc. (MRSN) reported $33.2M in revenue for fiscal year 2024. This represents a 220% increase from $10.4M in 2015.
Mersana Therapeutics, Inc. (MRSN) grew revenue by 9.9% over the past year. This is steady growth.
Mersana Therapeutics, Inc. (MRSN) reported a net loss of $70.1M for fiscal year 2024.
Mersana Therapeutics, Inc. (MRSN) has a return on equity (ROE) of -505.1%. Negative ROE indicates the company is unprofitable.
Mersana Therapeutics, Inc. (MRSN) had negative free cash flow of $74.4M in fiscal year 2024, likely due to heavy capital investments.